Literature DB >> 1917138

Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules.

E F Adams1, T Todo, U M Schrell, P Thierauf, M C White, R Fahlbusch.   

Abstract

We have used cell-culture techniques to investigate growth-factor production by human meningioma cells. Meningioma tissue was dispersed with collagenase and the cells grown to high density in tissue-culture flasks. The cultures were used to generate conditioned medium (MEN-CM), which was used to cultivate IMR32 cells (a human neuroblastoma line) and freshly dispersed primary meningioma cells. MEN-CM profoundly stimulated the in vitro growth of both IMR32 and meningioma cells. In addition, H3-thymidine uptake by cultured meningioma cells was increased in a dose-dependent manner by varying concentrations of MEN-CM. A neutralizing anti-body against platelet-derived growth factor (PDGF) completely abolished the stimulatory effects of MEN-CM, whereas an antibody against TGF-alpha was without effect. The mitogenic activity of MEN-CM, as assayed by promotion of H3-thymidine uptake by cultured meningioma cells, eluted from a Sephadex G-100 column in 3 peaks corresponding to molecular weights of greater than or equal to 150, 56 and 28 kDa. Our results show that proliferation of human meningiomas may be under autocrine control via secretion of PDGF-like molecules.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1917138     DOI: 10.1002/ijc.2910490315

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

2.  Human meningiomas possess muscarinic acetylcholine receptors: stimulation of phosphatidylinositol turnover by carbachol.

Authors:  E F Adams; A Hüttner; T Lei; B Rafferty; U Schrell; R Fahlbusch
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

Review 3.  Aberrant signaling pathways in meningiomas.

Authors:  Brian T Ragel; Randy L Jensen
Journal:  J Neurooncol       Date:  2010-09-14       Impact factor: 4.130

4.  Meningiomas expressing and responding to cholecystokinin (CCK).

Authors:  Eftychia Oikonomou; Ana L Machado; Michael Buchfelder; Eric F Adams
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

5.  Molecular genetic changes in a series of neuroepithelial tumors of childhood.

Authors:  Alessia Di Sapio; Isabella Morra; Luca Pradotto; Marilena Guido; Davide Schiffer; Alessandro Mauro
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

6.  Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma.

Authors:  J I Kuratsu; H Seto; M Kochi; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

7.  Involvement of protein kinase C in growth regulation of human meningioma cells.

Authors:  T Todo; R Fahlbusch
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas.

Authors:  Mahlon D Johnson; Mary O'Connell; Fran Vito; Robert S Bakos
Journal:  J Neurooncol       Date:  2008-11-26       Impact factor: 4.130

Review 9.  The role of PDGF in radiation oncology.

Authors:  Minglun Li; Verena Jendrossek; Claus Belka
Journal:  Radiat Oncol       Date:  2007-01-11       Impact factor: 3.481

10.  PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss.

Authors:  Matthieu Peyre; Céline Salaud; Estelle Clermont-Taranchon; Michiko Niwa-Kawakita; Stephane Goutagny; Christian Mawrin; Marco Giovannini; Michel Kalamarides
Journal:  Oncotarget       Date:  2015-10-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.